Emerging strategies to target RAS signaling in human cancer therapy

RAS mutations (HRAS, NRAS, and KRAS) are among the most common oncogenes, and around 19% of patients with cancer harbor RAS mutations. Cells harboring RAS mutations tend to undergo malignant transformation and exhibit malignant phenotypes. The mutational status of RAS correlates with the clinicopath...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Kun, Zhang, Yalei, Qian, Ling, Wang, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299671/
https://www.ncbi.nlm.nih.gov/pubmed/34301278
http://dx.doi.org/10.1186/s13045-021-01127-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299671/
https://www.ncbi.nlm.nih.gov/pubmed/34301278
http://dx.doi.org/10.1186/s13045-021-01127-w

Ejemplares similares